جميع الدراسات
نشط غير مجندالمرحلة 1تدخلي

Study of GS-4528 in Adults With Solid Tumors

This important study is looking into a new treatment called GS-4528 for adults who have solid cancers. Researchers are testing GS-4528 by itself and also alongside another drug called Zimberelimab. The main goals are to check if these treatments are safe and if people can tolerate them well. They also want to find the best and safest dose of GS-4528 to use in the future, both on its own and when given with Zimberelimab. This type of early study helps doctors understand how new medicines work in the body before they can be used more widely, offering hope for new ways to fight cancer.

نظرة سريعة

الحالة
نشط غير مجند
المرحلة
المرحلة 1
الراعي
علوم جلعاد
الهدف من التسجيل
182
ابدأ
11 May 2023
التاريخ المتوقع للانتهاء
01 أكتوبر 2026

ما هو موضوع هذه الدراسة؟

This clinical study is like an early step in finding new treatments for solid cancers. Researchers are focusing on a new drug called GS-4528. They want to see how safe it is and how well people can tolerate it. They are testing GS-4528 in two ways: first, on its own, and second, in combination with another approved cancer drug called Zimberelimab. This is important because combining treatments can sometimes be more effective than using just one.

The main purpose of this study is to find the right amount, or 'dose,' of GS-4528 that works best while still being safe. They will test different doses to make sure it's well-tolerated. Finding the right dose is key for any new medicine. This study is aimed at adults who have solid cancers.

By taking part, individuals contribute to medical knowledge and help researchers understand if GS-4528 could become a useful new treatment option in the future. This kind of research is vital for developing better ways to treat cancer and improve patients' lives, even though it's an early stage of investigation.

النقاط الرئيسية

  • This study is for adults with solid cancers that haven't responded to, or can't receive, other treatments.
  • It's testing a new drug, GS-4528, alone or with Zimberelimab, to check safety and find the best dose.
  • Participation involves regular clinic visits, blood tests, scans, and tissue samples.
  • This is an early-stage (Phase 1) study focused on understanding how the new drug works.
  • يمكنك الانسحاب من الدراسة في أي وقت.
  • The study helps develop potential new cancer treatments for the future.

من قد يكون مؤهلاً؟

To join this study, you would generally need to be an adult with a solid tumour that has either not responded to other treatments, or you couldn't take those treatments, or they caused too many problems. We would also need to see that your general health is good, for example, your body's organs like your liver and kidneys are working well.

You would need to have cancer that we can measure properly, usually with scans. Also, if you are a woman who could become pregnant, you would need to agree to use effective birth control during the study.

There are also reasons why someone might not be able to join. For example, if you are pregnant or breastfeeding, or if you've recently had other major cancer treatments, surgery, or radiation therapy within a certain time frame. Having certain other medical conditions or having had a transplant in the past would also prevent you from joining.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Are you an adult with a solid cancer?
  2. Has your cancer either not responded to other treatments, or are you unable to take them?
  3. Is your general health, including your organ function, considered good?
  4. If you are a woman able to have children, are you willing to use birth control?
  5. Have you not had any major cancer treatments (like surgery, chemo, radiation) very recently?
  6. هل أنتِ لستِ حاملاً أو مرضعة؟
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, you would first have a thorough check-up to make sure you're eligible. During the study, you would receive the new drug, GS-4528, either on its own or in combination with Zimberelimab. This would involve regular visits to the clinic for medical examinations, blood tests, and scans to monitor your health and how the treatment is affecting you and your cancer. You would also need to provide a small sample of your tumour tissue before starting the treatment.

For some participants, an additional tumour sample might be needed during the treatment to look at how the drug is working. The study team would closely monitor you for any side effects and manage them as needed. The total duration of your participation would be explained by the study team, and it would involve ongoing check-ins and follow-up appointments.

المخاطر والفوائد المحتملة

Participating in this study might offer a potential benefit of receiving a new cancer treatment that is not yet widely available; however, it's important to remember that this is an early-stage study, and the exact benefits are not known. There are potential risks, as with any medical treatment, including side effects from the study drugs. These side effects will be carefully monitored by the medical team. You are always in control and have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

المواقع (16)

  • The University of Washington/FHCC
    الرمز البريدي المؤكد
    سياتل، الولايات المتحدة
  • مستشفى أوتاوا
    الرمز البريدي المؤكد
    أوتاوا، كندا
  • شبكة الصحة الجامعية، مركز الأميرة مارغريت للسرطان
    الرمز البريدي المؤكد
    تورونتو، كندا
  • Asan Medical Center
    الرمز البريدي المؤكد
    سيول، كوريا الجنوبية
  • Severance Hospital, Yonsei University Health Systems
    الرمز البريدي المؤكد
    سيول، كوريا الجنوبية
  • Samsung Medical Center
    الرمز البريدي المؤكد
    سيول، كوريا الجنوبية
  • NEXT Oncology-Hospital Quironsalud Barcelona - Unidad de Ensayos Fase 1
    الرمز البريدي المؤكد
    برشلونة، إسبانيا
  • Hospital Universitari Vall D'Hebron- Oncology Service
    الرمز البريدي المؤكد
    برشلونة، إسبانيا
  • START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I
    الرمز البريدي المؤكد
    مدريد، إسبانيا
  • START MADRID_HM Sanchinarro-CIOCC-Unidad de Ensayos Fases I
    الرمز البريدي المؤكد
    مدريد، إسبانيا
  • Clinica Universidad de Navarra- Unidad Central de Ensayos Clinicos
    الرمز البريدي المؤكد
    بنبلونة، إسبانيا
  • Taichung Veterans General Hospital
    الرمز البريدي المؤكد
    تايتشونغ، تايوان

أسئلة شائعة

ما هو "الورم الصلب"؟

A solid tumour is a mass of abnormal tissue that doesn't contain cysts or liquid areas, like cancers of the lung, breast, or bowel.

ماذا يعني دراسة 'المرحلة 1'؟

A Phase 1 study is the first stage of testing a new drug in people. It mainly checks if the drug is safe, if people can tolerate it, and what the best dose might be.

What is 'monotherapy'?

Monotherapy simply means that you would receive only one treatment (GS-4528) by itself, without other cancer drugs at the same time.

Will I know if I'm getting GS-4528 alone or with Zimberelimab?

The study team will explain exactly which treatment group you would be in and what drugs you would receive.

What are 'measurable disease' and 'organ function'?

Measurable disease means your cancer can be accurately sized, usually on scans. Good organ function means your body's main organs are healthy enough to take part in the study.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.